Johns Hopkins researchers warn that the drug industry is exploiting a law meant to help unprofitable drugs meant to treat small populations with rare diseases to get big, blockbuster medications onto the market.…
An FDA investigation into the potential side effects of Revlimid, a medication for treatment of multiple myeloma, suggests that users may face an increased risk of developing new types of cancer. …
Federal health officials indicate that recent clinical trials suggest that side effects of Revlimid, which is used to treat blood cancer or bone marrow disorders, may increase the risk that users develop new types of cancer.…
According to Cephalon, Inc., at least two users of their cancer drug Treanda developed a severe form of the skin condition Stevens-Johnson syndrome, known as toxic epidermal necrolysis, and at least one has died. As a result, the drug’s warning label will be updated about the risk of using the drug in combination with allopurinol.…
According to drug maker Celgen Corp., the FDA will likely update the warning label for their blood-cancer drug Revlimid to indicate that side effects of the medication could lead to potentially fatal skin reactions such as Stevens-Johnson syndrome (SJS) or toxic epidermal necrolysis (TEN).…
The blood-cancer drug Revlimid has been associated with the development of rare and potentially fatal skin reactions known as Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN).…
